Business context and reporting period
Entity mismatch: The supplied filing is OmniLit Acquisition Corp.’s Form 10-Q, not a filing for Syntec Optics Holdings, Inc. This summary reflects the filing provided. It covers the quarter and six months ended June 30, 2022, and was signed August 10, 2022.
OmniLit is a blank-check company formed to pursue a business combination. It had not selected a target, commenced substantive target discussions, or generated operating revenue by June 30, 2022.
Key financial metrics
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Operating costs | $137,279 | $321,163 |
| Trust-account investment income | $208,234 | $220,201 |
| Net income (loss) | $64,568 | $(107,349) |
| Basic and diluted earnings (loss) per share | $0.01 | $(0.01) |
| Cash used in operating activities | $(319,178) for the six months |
At June 30, 2022, cash outside the trust was $283,149; trust-account securities and cash were $146,672,717; total assets were $147,205,811; and total liabilities were $5,120,283, including a $5,031,250 deferred underwriting discount payable only if a business combination closes. There was no long-term debt. Public shares classified as temporary equity totaled $146,625,000.
No meaningful operating margins are reported because the company had no operating revenue. The filing’s MD&A cash-flow discussion cites a net loss of $106,068, whereas the financial statements report $107,349 for the six-month period; the filing does not explain the difference.
Changes versus comparable periods
Cash outside the trust declined from $494,599 at December 31, 2021 to $283,149 at June 30, 2022. Trust-account assets rose from $146,626,679 to $146,672,717. The company reported a second-quarter profit, primarily because trust investment income exceeded operating costs and income tax expense; the six-month period remained loss-making. The filing compares 2022 results with the period from inception through June 30, 2021, when the company had no income or operating costs, rather than with a comparable prior-year quarter.
Outlook, risks and unusual items
- The company planned to complete a business combination before its scheduled February 12, 2023 liquidation deadline. It could extend the deadline twice by three months, to as late as August 12, 2023, subject to board action and sponsor funding of $1,437,500 per extension.
- Management said working capital and borrowing capacity were expected to cover needs through a business combination or one year from the filing. The sponsor had committed access to an additional $100,000 if needed; none had been drawn by June 30, 2022. Management also disclosed that the looming liquidation deadline raises substantial doubt about continued operations if no combination occurs and no extension is obtained.
- If no combination is completed within the permitted period, public shares are to be redeemed from the trust and the company liquidated. Trust funds may be subject to creditor claims, and the filing says the sponsor’s ability to meet its trust-indemnity obligation cannot be assured.
- Potential additional financing may be needed to complete a combination or address redemptions. No working-capital loans were outstanding at quarter-end. COVID-19 and the war in Ukraine were identified as uncertainties whose specific effects could not be determined.
- There was no material litigation, no reported material change to previously disclosed risk factors, and no material subsequent event identified. Management reported effective disclosure controls and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: the provided 10-Q is for OmniLit Acquisition Corp., not Syntec Optics Holdings, Inc.
- Verify business-combination status, deadline-extension decisions, and any sponsor extension funding.
- Assess available cash outside the trust, ongoing search and transaction costs, and whether additional financing will be required.
- Review trust-account redemption terms, creditor exposure, deferred underwriting fees, and sponsor indemnity capacity.
- Reconcile the MD&A cash-flow narrative’s $106,068 net-loss figure with the financial statements’ $107,349 six-month net loss.